Could nasal nitric oxide help to mitigate the severity of COVID-19?
Identifieur interne : 000012 ( Main/Exploration ); précédent : 000011; suivant : 000013Could nasal nitric oxide help to mitigate the severity of COVID-19?
Auteurs : Jan Martel [Taïwan] ; Yun-Fei Ko [Taïwan] ; John D. Young [Taïwan] ; David M. Ojcius [France]Source :
- Microbes and infection [ 1769-714X ]
Descripteurs français
- KwdFr :
- Administration par voie nasale (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Charge virale (effets des médicaments et des substances chimiques), Humains (MeSH), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (traitement médicamenteux), Monoxyde d'azote (administration et posologie), Monoxyde d'azote (usage thérapeutique), Pandémies (prévention et contrôle), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (traitement médicamenteux).
- MESH :
- administration et posologie : Monoxyde d'azote.
- effets des médicaments et des substances chimiques : Betacoronavirus, Charge virale.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Monoxyde d'azote.
- Administration par voie nasale, Humains.
English descriptors
- KwdEn :
- Administration, Intranasal (MeSH), Betacoronavirus (drug effects), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Humans (MeSH), Nitric Oxide (administration & dosage), Nitric Oxide (therapeutic use), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), Viral Load (drug effects).
- MESH :
- chemical , administration & dosage : Nitric Oxide.
- drug effects : Betacoronavirus, Viral Load.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- chemical , therapeutic use : Nitric Oxide.
- Administration, Intranasal, Humans.
Abstract
The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail.
DOI: 10.1016/j.micinf.2020.05.002
PubMed: 32387333
PubMed Central: PMC7200356
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Could nasal nitric oxide help to mitigate the severity of COVID-19?</title><author><name sortKey="Martel, Jan" sort="Martel, Jan" uniqKey="Martel J" first="Jan" last="Martel">Jan Martel</name><affiliation wicri:level="1"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan</wicri:regionArea><wicri:noRegion>Taoyuan</wicri:noRegion></affiliation></author><author><name sortKey="Ko, Yun Fei" sort="Ko, Yun Fei" uniqKey="Ko Y" first="Yun-Fei" last="Ko">Yun-Fei Ko</name><affiliation wicri:level="1"><nlm:affiliation>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City</wicri:regionArea><wicri:noRegion>New Taipei City</wicri:noRegion></affiliation></author><author><name sortKey="Young, John D" sort="Young, John D" uniqKey="Young J" first="John D" last="Young">John D. Young</name><affiliation wicri:level="1"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Ojcius, David M" sort="Ojcius, David M" uniqKey="Ojcius D" first="David M" last="Ojcius">David M. Ojcius</name><affiliation wicri:level="3"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA; University of Paris, Paris, France. Electronic address: dojcius@pacific.edu.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA; University of Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 May - Jun</date><idno type="RBID">pubmed:32387333</idno><idno type="pmid">32387333</idno><idno type="doi">10.1016/j.micinf.2020.05.002</idno><idno type="pmc">PMC7200356</idno><idno type="wicri:Area/Main/Corpus">001377</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001377</idno><idno type="wicri:Area/Main/Curation">001377</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001377</idno><idno type="wicri:Area/Main/Exploration">001377</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Could nasal nitric oxide help to mitigate the severity of COVID-19?</title><author><name sortKey="Martel, Jan" sort="Martel, Jan" uniqKey="Martel J" first="Jan" last="Martel">Jan Martel</name><affiliation wicri:level="1"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan</wicri:regionArea><wicri:noRegion>Taoyuan</wicri:noRegion></affiliation></author><author><name sortKey="Ko, Yun Fei" sort="Ko, Yun Fei" uniqKey="Ko Y" first="Yun-Fei" last="Ko">Yun-Fei Ko</name><affiliation wicri:level="1"><nlm:affiliation>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City</wicri:regionArea><wicri:noRegion>New Taipei City</wicri:noRegion></affiliation></author><author><name sortKey="Young, John D" sort="Young, John D" uniqKey="Young J" first="John D" last="Young">John D. Young</name><affiliation wicri:level="1"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Ojcius, David M" sort="Ojcius, David M" uniqKey="Ojcius D" first="David M" last="Ojcius">David M. Ojcius</name><affiliation wicri:level="3"><nlm:affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA; University of Paris, Paris, France. Electronic address: dojcius@pacific.edu.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA; University of Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Microbes and infection</title><idno type="eISSN">1769-714X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal (MeSH)</term><term>Betacoronavirus (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Humans (MeSH)</term><term>Nitric Oxide (administration & dosage)</term><term>Nitric Oxide (therapeutic use)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale (MeSH)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Charge virale (effets des médicaments et des substances chimiques)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Monoxyde d'azote (administration et posologie)</term><term>Monoxyde d'azote (usage thérapeutique)</term><term>Pandémies (prévention et contrôle)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nitric Oxide</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Monoxyde d'azote</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term><term>Charge virale</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nitric Oxide</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Monoxyde d'azote</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32387333</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-714X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4-5</Issue><PubDate><MedlineDate>2020 May - Jun</MedlineDate></PubDate></JournalIssue><Title>Microbes and infection</Title><ISOAbbreviation>Microbes Infect.</ISOAbbreviation></Journal><ArticleTitle>Could nasal nitric oxide help to mitigate the severity of COVID-19?</ArticleTitle><Pagination><MedlinePgn>168-171</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1286-4579(20)30080-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.micinf.2020.05.002</ELocationID><Abstract><AbstractText>The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail.</AbstractText><CopyrightInformation>Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martel</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Yun-Fei</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Biotechnology Corporation, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojcius</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA; University of Paris, Paris, France. Electronic address: dojcius@pacific.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Microbes Infect</MedlineTA><NlmUniqueID>100883508</NlmUniqueID><ISSNLinking>1286-4579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Microbes Infect. 2020 May - Jun;22(4-5):149-150</RefSource><PMID Version="1">32425647</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Breathing</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Coronavirus</Keyword><Keyword MajorTopicYN="Y">Innate immunity</Keyword><Keyword MajorTopicYN="Y">Nitric oxide</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Y.-F.K. is President of Chang Gung Biotechnology Corporation. J.D.Y. is Chairman of the Board of Chang Gung Biotechnology Corporation. D.M.O. is an editor with Microbes and Infection. The other author (J.M.) declares that no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32387333</ArticleId><ArticleId IdType="pii">S1286-4579(20)30080-0</ArticleId><ArticleId IdType="doi">10.1016/j.micinf.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200356</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Taïwan</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="Taïwan"><noRegion><name sortKey="Martel, Jan" sort="Martel, Jan" uniqKey="Martel J" first="Jan" last="Martel">Jan Martel</name></noRegion><name sortKey="Ko, Yun Fei" sort="Ko, Yun Fei" uniqKey="Ko Y" first="Yun-Fei" last="Ko">Yun-Fei Ko</name><name sortKey="Young, John D" sort="Young, John D" uniqKey="Young J" first="John D" last="Young">John D. Young</name></country><country name="France"><region name="Île-de-France"><name sortKey="Ojcius, David M" sort="Ojcius, David M" uniqKey="Ojcius D" first="David M" last="Ojcius">David M. Ojcius</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000012 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000012 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32387333
|texte= Could nasal nitric oxide help to mitigate the severity of COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32387333" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |